EGFR and exanthem: Non-small cell lung cancer (NSCLC) patients treated with erlotinib, an EGFR-TKI, show altered differentiation of the pilosebaceous epithelium as the primary process of EGFR inhibition in the human skin and is hypothesized as a trigger of inflammation and skin rash [6].